Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- π¨π³
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Effect of Ciclosporin Eyedrops on SjΓΆgren Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hospital Hietzing
- Target Recruit Count
- 12
- Registration Number
- NCT04597762
- Locations
- π¦πΉ
Augenabteilung - Klinik Hietzing, Vienna, Austria
Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Thomas Chester, OD
- Target Recruit Count
- 30
- Registration Number
- NCT04555694
- Locations
- πΊπΈ
Cleveland Eye Clinic, Brecksville, Ohio, United States
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 160
- Registration Number
- NCT04547049
- Locations
- π¨π³
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
π¨π³The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
π¨π³The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04542252
- Locations
- π―π΅
Research Site, Hachioji-shi, Tokyo, Japan
Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2020-09-07
- Target Recruit Count
- 200
- Registration Number
- NCT04540926
- Locations
- π²π½
Jose Luis Jl Galvez-Romero, Puebla, Mexico
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04537689
- Locations
- πΈπ¬
Singapore General Hospital, Outram Park, Singapore
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04532918
- Locations
- π©πͺ
Research Site, Berlin, Germany
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Conditions
- Refractory Malignant Peripheral Nerve Sheath TumorEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmDesmoplastic Small Round Cell TumorRecurrent Malignant Peripheral Nerve Sheath TumorRefractory Desmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04530487
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Tear Film Markers in Dry Eye Syndrome
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Vishal Jhanji
- Registration Number
- NCT04515329
- Locations
- πΊπΈ
UPMC Eye Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.